Mark Gelfand has more than 25 years of experience developing medical devices in academic, startup and corporate environments. His expertise is in integrative physiology, systems engineering and intellectual property. With Dr. Levin, he co-founded Axon Therapies, Soffio Medical, Cibiem, CHF Solutions, Ardian and Respicardia and served as the chief technology officer to those ventures.
Mr. Gelfand also worked at Nellcor Puritan Bennett, the world’s leading respiratory device company, where he was responsible for the architecture development of a new ICU ventilator platform. Prior to Nellcor, he was co-founder and chief technology officer of CardioLogic Systems Inc., where he was responsible for the development of the Vest CPR device designed to treat cardiac arrest. The successor to that device is now marketed as AutoPulse® by Zoll Medical.
From 1987 to 1992, Mr. Gelfand was senior research engineer in the division of cardiology at The Johns Hopkins School of Medicine, responsible for the development of several concept-level medical devices.
Mr. Gelfand is an author and co-author of more than 100 issued U.S. patents in the fields of heart failure, resuscitation, sleep apnea and dialysis. He holds master’s degrees in electrical engineering from St. Petersburg Institute of Technology and received graduate-level training in physiology at The Johns Hopkins School of Medicine.
Mr. Gelfand is an adjunct associate professor of biomedical engineering at Columbia University, lecturers and mentors students at Mount Sinai and Johns Hopkins Medical Schools and serves on the External Advisory Board of the Johns Hopkins University Center for Bioengineering Innovation & Design.